Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Model scores of the 29,894 trials active now.

Model score 21% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-10-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartanginacoronarytransplantventricular
  Phrases that lowered it: drughealthbloodinteractionindividuals
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.6% (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 12.7% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 726 (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 152 (lowers risk) · Sponsor's track record
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 95132 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 74.2% (lowers risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 9800 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI NCT03236311 · started 2017 · scored riskier than 59% of active trials terminated
• A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction NCT02452515 · started 2015 · scored riskier than 24% of active trials completed
• Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina NCT01659580 · started 2012 · scored riskier than 48% of active trials completed
• Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI) NCT01442038 · started 2011 · scored riskier than 85% of active trials completed
• Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study) NCT00824005 · started 2009 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.